Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Sep 24 · inside the Ichimoku cloud · RSI 47 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $321.1K | 0.00% | 12.37K | −75% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SRZN trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 21, 2026 | Tcg Crossover Gp Ii, L.L.CBeneficial Owner of more than 10% of a Class of Security | Sale at price 21.25 per share. | 325K | $6.91M |
| Jun 14, 2026 | Williams Charles OChief Operating Officer | Stock Award(Grant) at price 23.14 per share. | 1.7K | $38.55K |
| Jun 14, 2026 | Parker Craig CChief Executive Officer | Stock Award(Grant) at price 23.14 per share. | 1.6K | $37.53K |
| Jun 14, 2026 | Li YangOfficer | Stock Award(Grant) at price 23.14 per share. | 1.7K | $38.55K |
| Jun 14, 2026 | Maleki Andrew PedrumChief Financial Officer | Stock Award(Grant) at price 19.01 per share. | 607 | $11.54K |
| May 3, 2026 | Williams Charles OChief Operating Officer | Sale at price 33.33 per share. | 2K | $67.87K |
| May 3, 2026 | Parker Craig CChief Executive Officer | Sale at price 33.33 per share. | 4.5K | $150.80K |
| May 3, 2026 | Li YangOfficer | Sale at price 33.33 per share. | 1.6K | $52.80K |
| Apr 30, 2026 | Williams Charles OChief Operating Officer | — | 5.6K | — |
| Apr 30, 2026 | Parker Craig CChief Executive Officer | — | 12.5K | — |
| Apr 30, 2026 | Li YangOfficer | — | 4.4K | — |
| Mar 30, 2026 | Li YangOfficer | Stock Gift at price 0.00 per share. | 1.7K | — |
| Mar 23, 2026 | Tcg Crossover Gp Ii, L.L.CBeneficial Owner of more than 10% of a Class of Security | Purchase at price 24.69 - 24.90 per share. | 121.9K | $3.01M |
| Mar 15, 2026 | Tcg Crossover Gp Ii, L.L.CBeneficial Owner of more than 10% of a Class of Security | Purchase at price 24.88 - 24.99 per share. | 49K | $1.22M |
| Feb 11, 2026 | Tcg Crossover Gp Ii, L.L.CBeneficial Owner of more than 10% of a Class of Security | Purchase at price 23.58 - 23.86 per share. | 18.9K | $444.84K |
| Feb 2, 2026 | Tcg Crossover Gp Ii, L.L.CBeneficial Owner of more than 10% of a Class of Security | Purchase at price 21.38 - 21.94 per share. | 9.4K | $202.53K |
| Jan 19, 2026 | Column Group Iii Gp, L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 19.60 - 20.00 per share. | 32.5K | $641.60K |
| Jan 19, 2026 | Kutzkey TimDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 19.60 - 20.00 per share. | 32.5K | $641.60K |
| Jan 13, 2026 | Column Group Iii Gp, L.PBeneficial Owner of more than 10% of a Class of Security | Purchase at price 19.80 - 19.99 per share. | 18K | $357.35K |
| Jan 13, 2026 | Kutzkey TimDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 19.80 - 19.99 per share. | 18K | $357.35K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.7 | 29.0 | 4.8 | 14.7 | -21.5 | -1.0 | -14.4 | -0.9 | 46.1 | -26.9 | +4.0% | ||
| 2025 | -19.2 | -1.2 | 1.7 | -5.6 | -22.9 | 5.3 | 11.9 | 21.9 | 5.7 | 8.7 | 18.4 | 36.3 | +57.5% |
| 2024 | -16.0 | 64.6 | 20.8 | -31.5 | 4.2 | -2.3 | -26.4 | 32.0 | 12.6 | 12.2 | -9.2 | 17.6 | +52.7% |
| 2023 | 21.5 | 39.7 | -39.1 | 2.2 | 0.8 | -11.3 | 40.4 | -28.9 | -10.7 | -22.0 | 25.7 | 30.6 | +7.7% |
| 2022 | -62.9 | 26.4 | -0.3 | -14.6 | -3.5 | 21.0 | -15.0 | 0.8 | -21.4 | 13.5 | -73.8 | -3.0 | −91.0% |
| 2021 | -4.4 | -5.6 | 2.4 | 0.2 | 0.6 | 0.4 | -22.0 | -9.0 | -1.1 | 29.6 | -29.0 | −39.6% |
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Buy / hold / sell counts